New award for bumetanide tablets with sandoz INC. Period of performance is may 30, 2021 to may 29, 2022 with four one-year options.

Ended Indefinite Delivery Contract Awarded Last action

Contract number
36E79721D0011
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 100% complete
IDV ceiling
$9,803,319.55
Award type
Single award
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

This Indefinite Delivery Contract awards Sandoz Inc. a single-award contract through the Department of Veterans Affairs National Acquisition Center to supply bumetanide tablets to federal healthcare entities. The contract was awarded on May 30, 2021, with a ceiling value of $9.8 million and operates under the VA's prime vendor program, which streamlines pharmaceutical procurement and distribution to Veterans Affairs medical centers, Department of Defense facilities, the Bureau of Prisons, and Indian Health Services locations. The contract structure includes a base performance period from May 30, 2021, to May 29, 2022, followed by four one-year renewal options extending through May 29, 2026. No small business set-aside was utilized in this procurement, and the contract was awarded on an unrestricted basis, allowing ordering from Sandoz Inc.'s commercial catalog. The pre-solicitation opportunity was posted on October 2, 2020, with a due date of October 29, 2020, preceding the award by approximately seven months.

Bumetanide is a loop diuretic medication used to treat fluid overload and edema associated with congestive heart failure, liver cirrhosis, and renal disease. Under this contract, Sandoz Inc. supplies bumetanide tablets to meet the recurring pharmaceutical needs of federal beneficiaries including veterans, active duty military personnel, federal inmates, and Native American populations served through participating healthcare networks. The inclusion of a 2026 Small Business Subcontracting Plan into the contract demonstrates the government's commitment to supporting small business participation in the supply chain, despite the absence of a set-aside category in the primary award. This procurement exemplifies the VA's strategy of leveraging prime vendor relationships with established pharmaceutical manufacturers to ensure efficient, cost-effective access to essential generic medications across multiple federal agencies and healthcare delivery systems.

Transactions

Action Obligated Date
Add Subcontract Plan P00013 · Incorporation of 2026 small business subcontracting plan into contract 36E79721D0011 - bumetanide tablets. $0
Exercise an Option P00012 · Exercise option year 4, effective 05/30/2025 - 05/29/2026, for bumetanide tablets (36E79721D0011) with sandoz INC. $0
Add Subcontract Plan P00011 · Incorporation of 2025 small business subcontracting plan into contract 36E79721D0011 - bumetanide tablets. $0
Other Administrative Action P00010 · Change in manufacturing location. $0
Exercise an Option P00009 · Exercise option year 3, effective 05/30/2024 - 05/29/2025, for bumetanide tablets (36E79721D0011) with sandoz INC. $0
Other Administrative Action P00008 · Contractor administrative and sales POC change on contract. $0
Supplemental Agreement for work within scope P00007 · Modification for the supplemental changes to the CRF payment submittal and sales reporting requirements. $0
Add Subcontract Plan P00006 · Incorporation of 2024 small business subcontracting plan into contract 36E79721D0011 - bumetanide tablets. $0
Other Administrative Action P00005 · This modification is issued to incorporate the drug supply chain security act (DSCSA) language into the contract. $0
Exercise an Option P00004 · Exercise option year 2, effective 05/30/2023 - 05/29/2024 for bumetanide tablets (36E79721D0011) with sandoz INC. $0
Add Subcontract Plan P00003 · Incorporation of 2023 small business subcontracting plan into contract 36E79721D0011 - bumetanide tablets. $0
Exercise an Option P00002 · Exercise option year 1, effective 05/30/2022 - 05/29/2023 for bumetanide tablets (36E79721D0011) with sandoz INC. $0
Add Subcontract Plan P00001 · Incorporation of 2022 small business plan into contract 36E79721D0011 - bumetanide tablets $0
Original award $0
Show all 14

Quick answers

Who was awarded contract 36E79721D0011?

36E79721D0011 was awarded to Sandoz Inc. by National Acquisition Center (Headquarters) on May 30, 2021.

How much is contract 36E79721D0011 worth?

36E79721D0011's own ceiling is $9,803,320.

Who can order from contract 36E79721D0011?

36E79721D0011 is a single award indefinite delivery contract.

Was contract 36E79721D0011 competed?

The extent of competition for 36E79721D0011 was full and open competition. The government received 3 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV